CLAIMS:

1. Use of an oligomeric compound in the manufacture of a medicament for treating or ameliorating hereditary angioedema in a human subject in need thereof, wherein a therapeutically effective amount of the medicament is to be administered to the human subject, the oligomeric compound comprising the following chemical structure:



(SEQ ID NO: 4), or a salt thereof, optionally wherein the salt is the sodium salt or the potassium salt, wherein the therapeutically effective amount comprises any of the following dosage of the oligomeric compound:

80 mg;
100 mg;
75 mg to 80 mg;
80 mg to 85 mg;
75 mg to 85 mg;
95 mg to 100 mg; or
100 mg to 110 mg.

2. The use according to claim 1, wherein at least one symptom of hereditary angioedema is ameliorated and wherein the at least one symptom is selected from nausea, vomiting, itching, headache, fatigue, abdominal pain, shortness of breath, rhinitis, anaphylaxis, bronchoconstriction, and swelling, and a combination thereof.

3. The use according to claim 1 or claim 2, wherein the medicament is to be administered once every 4 weeks or once every 8 weeks.

4. The use according to any one of claims 1-3, wherein the medicament is to be administered once every 4 weeks, the medicament comprising 75 mg to 85 mg of the oligomeric compound.

5. The use according to claim 4, wherein the medicament is to be administered once every 4 weeks, the medicament comprising 80 mg of the oligomeric compound.

6. The use according to any one of claims 1-3, wherein the medicament is to be administered once every 8 weeks, the medicament comprising 75 mg to 85 mg of the oligomeric compound.

7. The use according to claim 6, wherein the medicament is to be administered once every 8 weeks, the medicament comprising 80 mg of the oligomeric compound.

8. The use according to any one of claims 1-3, wherein:

a) the medicament comprises 80 mg of the oligomeric compound and at least two doses of the medicament is to be administered to the human subject once every 4 weeks, and subsequently at least two doses of the medicament is to be administered to the human subject once every 8 weeks;

b) the medicament comprises 75 mg to 85 mg of the oligomeric compound and at least two doses of the medicament is to be administered to the human subject once every 4 weeks, and subsequently at least two doses of the medicament is to be administered to the human subject once every 4 weeks;

c) a first dosage of the medicament comprises 80 mg of the oligomeric compound and a second dosage of the medicament comprises 100 mg of the oligomeric compound, wherein at least two doses of the medicament at the first dosage is to be administered to the human subject once every 4 weeks,

and subsequently at least two doses of the medicament at the second dosage is to be administered to the human subject once every 4 weeks; or

d) a first dosage of the medicament comprises 75 mg to 85 mg of the oligomeric compound and a second dosage of the medicament comprises 95 mg to 100 mg or 100 mg to 110 mg of the oligomeric compound, wherein at least two doses of the medicament at the first dosage is to be administered to the human subject once every 4 weeks, and subsequently at least two doses of the medicament at the second dosage is to be administered to the human subject once every 4 weeks.

9. The use according to any one of claims 1-8, wherein

the hereditary angioedema is type I HAE, optionally wherein the human subject has a genetic mutation in the *SERPING1* gene;

the hereditary angioedema is type II HAE, optionally wherein the human subject has a genetic mutation in the *SERPING1* gene; or

the hereditary angioedema is type III HAE, optionally wherein the human subject has a genetic mutation in a gene selected from *F12*, *PLG*, and *ANGPT1*.

10. The use according to any one of claims 1-9, wherein the human subject is refractory to at least one anti-edema agent, optionally wherein the at least one anti-edema agent comprises a histamine inhibitor, a C1 esterase inhibitor, attenuated androgen, an antifibrinolytic agent, an angiotensin-converting enzyme inhibitor, an angiotensin II type 1 receptor blocker, a kallikrein inhibitor, a bradykinin B2 receptor antagonist, or a combination thereof.

11. The use according to any one of claims 1-10, wherein the human subject has an average of at least 1, at least 2, at least 3, at least 4, at least 5, or at least 6 angioedema attacks per month as measured over at least 1, 2, 3, 4, 5, 6, 8, or 12 months, before the medicament is to be administered.

12. The use according to any one of claims 1-11, wherein the medicament reduces the frequency of angioedema attacks by at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95%.

13. The use according to any one of claims 1-12, wherein the medicament reduces the frequency of angioedema attacks to an average of less than 2 or less than 1 attacks per month, as measured over 1, 2, 3, or 4 months during treatment of the human subject with the medicament.

14. The use according to any one of claims 1-13, wherein the medicament is to be administered by subcutaneous injection, optionally wherein the medicament is to be self-administered.

15. The use according to any one of claims 1-14, wherein the human subject has a mutation in the *SERPING1* gene, and wherein

the medicament is to be administered to the human subject every 4 weeks or every 8 weeks, the medicament comprising 80 mg of the oligomeric compound;

the human subject has an average of at least 1, at least 2, at least 3, at least 4, at least 5, or at least 6 angioedema attacks per month as measured over at least 1, 2, 3, 4, 5, 6, 8, or 12 months, before the medicament is to be administered; and

the human subject has an average of less than 2 or less than 1 angioedema attacks per month as measured over at least 1, 2, 3, or 4 months during treatment with the medicament.

16. The use according to any one of claims 1-15, wherein the oligomeric compound is formulated in sterile saline at a concentration of 100mg/ml.